ArticleCirculation. Heart failure2023
Improvement in Renal Function During the Treatment of Acute Decompensated Heart Failure: Relationship With Markers of Renal Tubular Injury and Prognostic Importance.
Article in Circulation. Heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Kidney Disease and Heart Failure: Recent Advances and Current Challenges: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.JACC. Heart failure · 2026Guideline
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Administration JMKX003142 in Chinese Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Single, and Multiple Ascending Dose Phase I Clinical Trial.Drug design, development and therapy · 2026Trial
- Volenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Trial
- Hypoperfusion-Shock Continuum in Acute Decompensated Heart Failure.Circulation. Heart failure · 2026Review
- Relationship Between Central Venous Pressure, Cardiac Index, and Renal Function in Pediatric Heart Failure: a Pediatric Heart Transplant Society Study.Pediatric cardiology · 2026Article
- Artificial intelligence-based method for renal function automatic assessment of each kidney using plain computed tomography (CT) scans.Physical and engineering sciences in medicine · 2026Article
- Decongestion in heart failure: medical and device therapies.Nature reviews. Cardiology · 2025Review
- Pharmacological options to relieve congestion in acute heart failure.Heart failure reviews · 2025Review
- Evaluation of neutrophil gelatinase-associated lipocalin (NGAL) levels as a biomarker for the early diagnosis of heart failure patients without of kidney disease.Journal of cardiovascular and thoracic research · 2025Article
- Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Biomarker of Acute Kidney Injury (AKI) in Dogs with Congestive Heart Failure (CHF) Due to Myxomatous Mitral Valve Disease (MMVD).Animals : an open access journal from MDPI · 2025Article
- How to Enhance Cardiorenal Benefits in Patients With Chronic Heart Failure?International journal of heart failure · 2025Review
Corrections and comments
- Commented on by
Authors and funding
11 authors at 7 institutions in 3 countries.
Funding
Abstract
backgroundImprovement in renal function (IRF) in acute decompensated heart failure is associated with adverse outcomes. The mechanisms driving this paradox remain undefined.
methodsUsing the ROSE-AHF study (Renal Optimization Strategies Evaluation-Acute Heart Failure), 277 patients were grouped according to renal function, with IRF defined by a ≥20% increase (N=75), worsening renal function by a ≥20% decline (N=53), and stable renal function (SRF) by a <20% change (N=149) in estimated glomerular filtration rate between baseline and 72 hours. Three well-validated renal tubular injury markers, NGAL (neutrophil gelatinase-associated lipocalin), NAG (N-acetyl-β-d-glucosaminidase), and KIM-1 (kidney injury molecule 1), were evaluated at baseline and 72 hours. Patients were also classified by the pattern of change in these markers.
resultsPatients with IRF had the lowest admission estimated glomerular filtration rate (IRF, 37 [28 to 51] mL/min per 1.73 m
conclusionsIRF during decongestive therapy for acute decompensated heart failure was not associated with improved markers of renal tubular injury and was associated with worsened survival, likely driven by the presence of greater underlying cardiorenal dysfunction and more severe congestion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.